Showing results (31-40 of 123) with videos related to

Sort By:
Pageof 13
Journal of Breast Cancer|January 16, 2016
Risk of Second Primary Malignancy in Breast Cancer Survivors: A Nested Population-Based Case-Control StudyRaffaella Marcheselli, Luigi Marcheselli, Laura Cortesi, et al.
Cancer|March 31, 2007
Introduction of rituximab in front-line and salvage therapies has improved outcome of advanced-stage follicular lymphoma patientsStefano Sacchi, Samantha Pozzi, Luigi Marcheselli, et al.
Haematologica|August 14, 2008
Second malignancies after treatment of diffuse large B-cell non-Hodgkin's lymphoma: a GISL cohort studyStefano Sacchi, Luigi Marcheselli, Alessia Bari, et al.
Oncotarget|November 24, 2016
The impact of reproductive life on breast cancer risk in women with family history or BRCA mutationAngela Toss, Giovanni Grandi, Angelo Cagnacci, et al.
Thrombosis Research|May 14, 2014
Non-activated plasma-derived PC improves amputation rate of children undergoing sepsisAndrea Piccin, Aengus O' Marcaigh, Corrina Mc Mahon, et al.
International Journal of Cancer|August 24, 2012
Tumor size, node status, grading, HER2 and estrogen receptor status still retain a strong value in patients with operable breast cancer diagnosed in recent yearsLaura Cortesi, Luigi Marcheselli, Valentina Guarneri, et al.
Leukemia & Lymphoma|June 14, 2011
Radiation therapy improves treatment outcome in patients with diffuse large B-cell lymphomaLuigi Marcheselli, Raffaella Marcheselli, Alessia Bari, et al.
Cancer Biology & Medicine|March 12, 2021
BRCA mutation rate and characteristics of prostate tumor in breast and ovarian cancer families: analysis of 6,591 Italian pedigreesLaura Cortesi, Federica Domati, Annalisa Guida, et al.
Hematological Oncology|April 25, 2024
Real-life study on the use of response adapted therapy in patients with Hodgkin Lymphoma: Results from a multicenter experienceVittorio Ruggero Zilioli, Emanuele Cencini, Sonya De Lorenzo, et al.
Annals of Hematology|September 18, 2010
Phase II fludarabine and cyclophosphamide for the treatment of indolent B cell non-follicular lymphomas: final results of the LL02 trial of the Gruppo Italiano per lo Studio dei Linfomi (GISL)Andrea Ferrario, Francesco Merli, Stefano Luminari, et al.
Pageof 13